Sitagliptin

• Description:

  Sitagliptin (MK-0431) is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes[1][2][3][4][5].

• Product Name Alternative:

  MK-0431

• UNSPSC:

  12352005

• Hazard Statement:

  H319, H373

• Target:

  Dipeptidyl Peptidase; Endogenous Metabolite; ERK; GLP Receptor; PKA

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/Sitagliptin.html

• Purity:

  99.94

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C (N1CC2=NN=C (C (F) (F) F) N2CC1) C[C@H] (N) CC3=CC (F) =C (F) C=C3F

• Molecular Formula:

  C16H15F6N5O

• Molecular Weight:

  407.31

• Precautions:

  H319, H373

• References & Citations:

  [1]Thomas, L., et al. (R) -8- (3-amino-piperidin-1-yl) -7-but-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008 Apr;325 (1) :175-82.|[2]Kim, S.J., et al., Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes, 2009. 58 (3) : p. 641-51.|[3]Sangle, G.V., et al., Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a GLP-1 secretagogue. Endocrinology, 2012. 153 (2) : p. 564-73.|[4]Kim, S.J., et al., Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes, 2008. 57 (5) : p. 1331-9.|[5]Beconi, M.G., et al. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos, 2007. 35 (4) : p. 525-32.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  DPP-4

• Citation 01:

  Arch Oral Biol. 2025 Jul:175:106253.|Biochem Pharmacol. 2023 Nov:217:115846.|Biochim Biophys Acta Mol Basis Dis. 2024 Jul 25:167433.|Cell Death Dis. 2021 Oct 11;12 (10) :928.|Exp Cell Res. 2024 Sep 12;442 (2) :114254.|Front Oncol. 2021 Sep 24:11:728047.|Int J Biol Macromol. 2025 Jun 6;318 (Pt 1) :145051.|iScience. 2023 Feb 27;26 (3) :106271.|J Adv Res. 2025 Aug:74:225-236.|J Biol Chem. 2018 Dec 7;293 (49) :18864-18878. |J Ethnopharmacol. 2025 Sep 9;355 (Pt A) :120587.|J Nanobiotechnology. 2024 Oct 16;22 (1) :631.|J Sep Sci. 2022 Jan;45 (2) :631-637.|Korean J Physiol Pharmacol. 2021 Sep 1;25 (5) :425-437.|Life Metab. 2025 Feb 8;4 (2) :loaf004.|Neurol Res. 2018 Sep;40 (9) :736-743.|Nutr Neurosci. 2019 Dec;22 (12) :877-893.|Nutrition. 2024 Dec:128:112565.|Orebro University. 2024.|Oxid Med Cell Longev. 2019 Nov 15;2019:6181754.|Oxid Med Cell Longev. 2022 May 17;2022:2586305.|Research Square Preprint. 2024 Apr 25.|Sci Rep. 2019 Mar 11;9 (1) :4074.|World J Diabetes. 2025 Jun 15;16 (6) :103616.|Biomed Pharmacother. 2023 Jun:162:114555.|bioRxiv. 2023 Nov 4.

• CAS Number:

  486460-32-6